Management of Atrial Fibrillation with Respiratory Distress

Initial Assessment

The American College of Cardiology recommends evaluating patients with atrial fibrillation and respiratory distress for signs of hemodynamic instability, including hypotension, acute heart failure, angina, or myocardial infarction 1
Identifying potential reversible causes of AF and respiratory distress, such as thyroid dysfunction, electrolyte abnormalities, infection, or pulmonary conditions, is crucial for effective management 1
Determining the duration of AF, if possible, impacts anticoagulation decisions, according to the European Heart Journal 1

The European Heart Journal recommends performing immediate electrical cardioversion without waiting for anticoagulation in patients with AF who have acute or worsening hemodynamic instability 2, 1
Administering heparin concurrently, if not contraindicated, reduces thromboembolic risk, as suggested by the European Heart Journal and Praxis Medical Insights 1
After stabilization, initiating appropriate oral anticoagulation for at least 4 weeks is recommended by the European Heart Journal 2

The European Heart Journal recommends beta-blockers, diltiazem, verapamil, or digoxin as first-line agents for patients with AF and LVEF >40% 2, 1
For patients with reduced ejection fraction (LVEF ≤40%), using beta-blockers and/or digoxin is recommended by the European Heart Journal and Praxis Medical Insights 2, 3
Starting with lower doses of rate-controlling medications and titrating carefully avoids excessive hypotension, especially in patients already taking vasodilators, as advised by Praxis Medical Insights 3

The Journal of the American College of Cardiology and Praxis Medical Insights suggest considering pharmacological cardioversion for patients with persistent respiratory symptoms despite rate control 4, 1
Intravenous amiodarone is recommended for cardioversion in patients with heart failure, severe left ventricular hypertrophy, or coronary artery disease by the European Heart Journal 2
Intravenous flecainide or propafenone can be used for recent-onset AF in patients without structural heart disease, according to the European Heart Journal 2
Intravenous vernakalant is an option for recent-onset AF in patients without severe aortic stenosis, heart failure with reduced ejection fraction, or recent acute coronary syndrome, as recommended by the European Heart Journal 2

The European Heart Journal and Praxis Medical Insights recommend therapeutic anticoagulation for at least 3 weeks before scheduled cardioversion of AF lasting >48 hours or of unknown duration 2, 1
If immediate cardioversion is needed but adequate anticoagulation has not been provided, performing transesophageal echocardiography to exclude cardiac thrombus is advised by the European Heart Journal and Praxis Medical Insights 2, 1
Continuing oral anticoagulation for at least 4 weeks after cardioversion and long-term in patients with thromboembolic risk factors is recommended by the European Heart Journal 2
Direct oral anticoagulants are preferred over vitamin K antagonists in eligible patients, according to the European Heart Journal 2

Failing to identify and treat reversible causes of AF and respiratory distress is a common pitfall, as noted by Praxis Medical Insights 1
Attempting cardioversion without appropriate anticoagulation in patients with AF lasting >48 hours is a pitfall to avoid, according to the European Heart Journal and Praxis Medical Insights 2, 1
Using digoxin as the sole agent for rate control in paroxysmal AF is not recommended by Praxis Medical Insights 1, 3